June 1, 2022
Breakthrough T1D Official Statement on the FDA Approval of Abbott’s FreeStyle Libre® 3
May 25, 2022
Avera Health, Breakthrough T1D, and the Helmsley Charitable Trust Partner to Provide Virtual Health Care to Schools in Underserved Communities
May 10, 2022
NexImmune, Yale, and Breakthrough T1D Enter into Research Partnership for Type 1 Diabetes
May 4, 2022
Breakthrough T1D Launches 2022 Fundraising Sweepstakes to Win a 2022 F-150® Lightning™ LARIAT
April 25, 2022
Breakthrough T1D UK: £50m donation for type 1 diabetes research to lead the race for a cure
April 11, 2022
Breakthrough T1D Official Statement on Bipartisan Policy Priorities to Lower Insulin Costs
April 11, 2022
Breakthrough T1D Announces the Appointment of New Board Leadership
April 6, 2022
Aspect Biosystems Announces Partnership with Breakthrough T1D to Advance Development of a Bioengineered Tissue Therapeutic to Treat Type 1 Diabetes
April 5, 2022
C-Path Receives Qualification Opinion from EMA on Type 1 Diabetes Biomarker Initiative
March 31, 2022
Breakthrough T1D Statement on the Passage of the Affordable Insulin Now Act by the U.S. House of Representatives
